A Randomized, Placebo-Controlled, Double-Blind, Parallel Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of LTI-291 in Patients with Parkinson's Disease and a GBA1 Mutation
Latest Information Update: 21 Sep 2018
At a glance
- Drugs LTI-291 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- 15 Sep 2018 Status changed from recruiting to completed.
- 30 Jan 2018 New trial record